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Does Better Rate Control
Improve Quality of Life?
Be Still My Beating Heart*
Paul Dorian, MD, MSC,† Andrew C. T. Ha, MD‡
Toronto, Ontario, Canada
“Cure sometimes, treat often, comfort always.”
—Hippocrates (1)
Guidelines for the management of atrial fibrillation (AF)
increasingly emphasize patient well-being as one of the
most important outcomes of successful therapy. Unfortu-
nately, no AF therapy has been clearly shown to reduce
mortality, and data demonstrating a reduction in major
morbidity, apart from the clearly understood reduction of
stroke, are limited (2,3). Practitioners are thus aware that a
primary goal of AF management is to reduce or mitigate
symptoms related to AF and its treatment. For most
patients, this will involve slowing of the rapid and irregular
ventricular rate that usually accompanies AF, either as the
initial or the exclusive goal of treatment (in addition to the
crucially important need to assess stroke risk and treat
appropriately).
See page 1795
However, patient well-being, often expressed as health-
related quality of life (QOL), is difficult to measure precisely
or even describe using commonly understood terminology.
Components of QOL are by definition subjective, and
understanding the impact of the AF condition in a partic-
ular patient requires the disentanglement of those aspects of
the illness that are directly or indirectly related to AF from
other symptoms or difficulties related to coexisting illnesses
(e.g., heart failure, pulmonary disease), symptoms or mental
states associated with other health-related problems, or the
effect of issues such as physical deconditioning, emotional
difficulties, and financial problems on health status. Fur-
thermore, an accurate understanding of the impact of AF
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articulate the extent to which the illness affects their daily
life functioning, as well as their assessment of the conse-
quences the illness and its treatment have on their individual
perceived health status. This is a difficult task.
It is tempting, and seems at first glance reasonable, to use
readily available and objective measures of cardiac function
in patients with AF as a surrogate for the assumed impact
on QOL. For example, many physicians may assume that a
rapid and irregular heart rate is undesirable, and implicitly
subjectively undesirable, compared with a slower, more
well-controlled rate. Similarly, it is often assumed that sinus
rhythm maintenance and restoration ought to be associated
with better QOL than persisting AF. Groenveld et al. (4),
in the current issue of the Journal, have contributed impor-
tantly to our understanding of the connection between
objective, electrocardiography-based measures of cardiac
function and subjective patient-related outcomes. In a
substudy of the RACE II (Rate Control Efficacy in Perma-
nent Atrial Fibrillation II) study (a randomized trial of
“strict” versus “lenient” rate control in patients with perma-
nent AF), they have added to the primary observation that
“strict rate control” (targeting a resting heart rate of 80
beats/min) compared with “lenient rate control” (targeting a
heart rate of 110 beats/min at rest) does not produce
meaningful improvement in major morbidity and mortality
(5). In this companion study, they assessed QOL in 437 of
the 614 patients enrolled in the RACE II study, using both
generic measures of QOL, such as the Medical Outcomes
Study 36-item Short-Form Health Survey (SF-36), and
more disease-related measures, including the AF severity
scale and the Multidimensional Fatigue Inventory-20, at
baseline and during long-term follow-up. In short, there
were no differences in general or disease-specific measures of
QOL or symptoms between the strict and lenient rate
control groups, and no meaningful changes over time in
these measures. QOL, as well as changes in this factor, was,
however, related to age, the severity of underlying heart
disease, the severity of symptoms, and sex. These results are
consistent with observations that have been made in both
cross-sectional and longitudinal studies of patients with AF
(population-based cohort studies as well as randomized
studies), which have shown that the strategy of AF treat-
ment (i.e., rate vs. rhythm control strategy) has limited to no
impact on QOL, and that the most important determinant
of general QOL is the degree of symptoms specifically
related to AF (e.g., dyspnea, palpitations, fatigue) (6,7). In
the FRACTAL (Fibrillation Registry Assessing Costs,
Therapies, Adverse Events and Lifestyle) cohort study of
963 patients with AF, the presence of AF and the “AF
burden” was not related to impairment in QOL (8), similar
to observations from the AFFIRM (Atrial Fibrillation
Follow-up Investigation of Rhythm Management) study (7).
There are some limitations to our ability to generalize
rom the important observations of Groenveld et al. (4).
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AF, a condition that has been suggested to be less conse-
quential on QOL than paroxysmal or persistent AF early in
the disease onset. Second, the differences in average ven-
tricular rate between the “strict” and the “lenient” groups of
patients were relatively modest, potentially limiting the
ability to perceive potential differences in QOL that may be
present between heart rates in the normal range (e.g., 60 to
70 beats/min) and heart rates near the upper limit of
guideline-recommended rates for adequate rate control
(e.g., 100 to 109 beats/min). Patients in the RACE II trial
had impaired QOL, but overall SF-36 scores were interme-
diate between age-standardized normal controls and SF-36
scores in patients reported in previous trials of AF, including
in the RACE I study of rate versus rhythm control pub-
lished by the same research group (9). The results of this
trial may thus apply primarily to patients with long-standing
and not terribly symptomatic AF.
However, in support of the generalizability of the results
from Groenveld et al. (4), previous studies of the relation
between heart rate and outcomes have shown directionally
similar results. For example, there is no relation between
heart rate and exercise capacity as measured by maximum
oxygen consumption in patients with AF (10). Other
studies have also failed to note a relation between heart rates
at rest and with exercise (11), or the ventricular rate after
treatment (12), and general well-being. In a large cohort
study of patients with recent-onset AF, baseline heart rate
was not related to QOL (13). In a study of various therapies
to slow ventricular responses during exercise, beta-blockers
were more effective than calcium-channel blockers at lim-
iting maximum exercise heart rate but were not associated
with changes in QOL or exercise tolerance, whereas
calcium-channel blockers tended to improve QOL (11). In
a summary analysis of multiple small randomized trials of
digoxin, beta-blockers, and calcium-channel blockers for
rate control during exercise in AF, beta-blockers were more
effective at slowing peak ventricular response but did not
increase or decrease maximum exercise tolerance. Calcium-
channel blockers, conversely, were less effective at heart rate
slowing but improved or had no effect on exercise tolerance
(14). These observations suggest that, at least for beta-
blocker therapy, the potential benefits of stricter rate control
on exercise capacity and well-being may be offset by adverse
effects such as fatigue or effort intolerance. The lack of QOL
benefit from strict rate control in the RACE II study may in
part be due to a potential symptomatic benefit from lower
heat rates offset by adverse effects resulting from the need
for more frequent use of beta-blockers, in higher doses, in
the strict rate control group compared with the lenient rate
control group.
In contrast to the disconnect between rate and rhythm
and QOL, studies consistently show that there are individ-
ual patient characteristics that tend to be associated with
poor QOL in AF. The most prominent of these are female
sex, invariably associated with poorer QOL than in men forthe same apparent degree of illness burden (6,15,16), the
presence of depression or pessimism as a stable personality
trait (17), and personality traits relating to the response to
physical and emotional stressors, such as anxiety sensitivity
and somatization (18), as well as more obvious factors, such
as the presence of heart failure and coexisting illnesses,
which are associated with poorer QOL. Older patients are
often less symptomatic than younger patients and tend to
have a different symptom pattern, with fatigue and dyspnea
being more prominent, whereas palpitations (an unpleasant
awareness of cardiac action) is more prominent in younger
patients (8,16).
Treatment of AF by catheter ablation may prove to be an
exception to the disappointingly small effect of strict rate or
rhythm control on QOL. Among patients with symptom-
atic, medically refractory paroxysmal AF, catheter ablation
has been associated with a marked and sustained improve-
ment of QOL (19). However, these results are tempered by
a recent study of 323 patients in which the improvement of
SF-36 QOL indices was unrelated to the ablation outcome
itself (20). This finding highlights the difficulty in objec-
tively assessing the QOL effect of AF ablation and raises the
possibility that the QOL benefits of AF ablation may in part
be related to a placebo effect of the procedure (20).
What clinical lessons can we draw from the observations
of Groenveld et al. (4)? Most important, it is insufficient to
merely examine the electrocardiogram of patients in AF to
assess the impact of their illness on their well-being. For
example, a resting ventricular response rate in AF of 100
beats/min does not necessarily imply the patient is worse off
than if his or her heart rate was 60 beats/min and should not
necessarily prompt the practitioner to intensify rate control
therapy. Because QOL is subjective, it has to be assessed
subjectively. There is no laboratory test, per se, for QOL.
Questionnaires used in research studies are valid measures of
the seemingly ethereal concept but are impractical for
routine clinical use. Global bedside estimations of QOL
have been proposed, including the Canadian Cardiovascular
Society’s Severity of Atrial Fibrillation scale (21) and the
European Society of Cardiology’s European Heart Rhythm
Association scale (2). These are simple-to-use global mea-
sures of the impact of AF and its treatment on patient
well-being. Clinicians need to be aware that patient person-
ality, treatment expectations, and factors unrelated to the
arrhythmia itself will have important, potentially determin-
ing influences on the extent to which AF causes suffering.
In an era of increasingly sophisticated and complex
technologies used to investigate and treat atrial fibrillation,
it is worth heeding the advice of Hippocrates (22): “It is far
more important to know what person the disease has than
what disease the person has.”
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